Docetaxel medicine
Bear HD et al. A randomized trial comparing preoperative preop ; doxorubicin cyclophosphamide AC ; to preop AC followed by preop docetaxel T ; and to preop AC followed by postoperative postop ; T in patients pts ; with operable carcinoma of the breast: Results of NSABP B-27. Presentation. San Antonio Breast Cancer Symposium, 2004; Abstract 26. Bear HD et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21 22 ; : 4165-74. Buzdar AU et al. Pathological complete response to chemotherapy is related to hormone receptor status. Breast Cancer Res Treat 2003; 82 Suppl 1 ; : 69; Abstract 302. Chollet P et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002; 86 7 ; : 1041-6. Fisher B et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16 8 ; : 2672-85. Green MC et al. Weekly wkly ; paclitaxel P ; followed by FAC as primary systemic chemotherapy PSC ; of operable breast cancer improves pathologic complete remission pCR ; rates when compared to every 3-week Q 3 wk ; P therapy tx ; followed by FAC -- Final results of a prospective phase III randomized trial. Proc ASCO 2002; Abstract 135. Hutcheon AW et al. Docetaxel primary chemotherapy in breast cancer: A five year update of the Aberdeen trial. Breast Cancer Res Treat 2003; Abstract 11. Kaufmann M et al. International expert panel on the use of primary preoperative ; systemic treatment of operable breast cancer: Review and recommendations. J Clin Oncol 2003; 21 13 ; : 2600-8.
Bengt Johansson, Lund Institute of Technology; J. Rey Agama, Caterpillar Inc.; Per Tunestal, Lund Institute of Technology; Scott B. Fiveland, Kevin P. Duffy, Caterpillar Inc. Paper No. Title.
Altogether, the results suggest that EGF-EGFR and SHH signaling cascades may play an important role for the sustained growth, survival, and invasion of prostate cancer cells during the progression from locally advanced prostate cancers into metastatic and recurrent disease states. Therefore, the combined use of docetaxel with both the selective inhibitors of EGFR and hedgehog signaling cascades, such as gefitinib and cyclopamine, may represent a promising strategy for improving the efficacy of current standard antihormonal and radiotherapeutic treatments used in the early stages against localized prostate cancers. Moreover, this triple combination could also be beneficial in late stages of advanced prostate cancer to eliminate the total population of metastatic HRPC cells in primary and secondary neoplasms and thereby prevent disease relapse. Hence, this novel combination of drugs offers a new alternative to current docetaxel-based regimens and may constitute a rational basis for future clinical trials to estimate its efficacy in patients with highly aggressive prostate cancers, which yet remain incurable in the clinics.
Docetaxel medicine
Fast and reliable installation without glue using the In&Out method. Produced under licence from Unilin Decor, Belgium. The ideal flooring for all living areas as well as for commercial areas with medium wear, e.g. hotel rooms, individual offices, conference rooms etc. Awarded for all MEISTER flooring 2008 92.
Figure 5. Progression-free survival curves A ; and overall survival curves B ; show that the survival rates of patients receiving docetaxel plus prednisone daily are statistically better than those receiving weekly docetaxel alone.
The FDA was ultimately rejected because it could not make a pill that was a bioequivalent to ACTOS.27 As a result, the second and docusate.
And felt that I had failed my family and my own personal goals. I even began to look into other careers. But fortunately, and with the support of my family, I took the test again Rebekah Kim and my scores considerably improved. Then I decided to wait after I graduated college to apply to medical schools. During several summers, through my involvement as a cello instructor at the Elizabeth Morrow School Summer String Music Festival, I had learned about The Arnold P. Gold Foundation. I felt lucky to have been accepted as a Foundation intern in September 2000. The next eight months were busily spent helping at The Foundation and in applying to medical schools. Through the process I discovered that most schools seemed to be even more inter13.
Neoadjuvant studies have failed to detect a predictive value to p53 staining with regards to chemoresponsiveness in breast cancers MacGrogan et al. 1996, Niskanen et al. 1997, Bonetti et al. 1998, Rozan et al. 1998 ; . Work by Geisler et al. 2001 ; has demonstrated that specific p53 mutations are associated with resistance to doxoubicin in the neoadjuvant setting. A number of these mutations were not associated with enhanced staining for p53, which would explain why immunohistochemical studies have been inconclusive. Assessment of p21 WAF1 cyp1 ; staining as a downstream marker of p53 activity improved the relationship between p53 staining and mutational status, but was not an absolute predictor of functional p53 Ellis et al. 1997c ; . The same group of investigators also demonstrated a strong correlation between p53 mutation and HER2 expression. In another study, p53 staining and mutations were studied in relation to the response of 67 breast tumours to neoadjuvant 5-fluorouracil epirubicin cyclosphate FEC ; or docetaxel chemotherapy. In the FEC group, treatment failure was associated with p53 mutation and absence of apoptotic cells after treatment. For paclitaxel treatment, in which the role of p53-mediated cell death is less clear Lanni et al. 1997 ; , a response was supported by deficient p53 and normal p53 was associated with resistance Kandioler-Eckersberger et al. 2000 ; . Overexpression of Bcl-XL, a related member of the Bcl-2 family, promotes chemotherapy resistance of mammary tumours in a syngeneic mouse model Liu et al. 1999 ; , but clinical data are currently lacking. In contrast, reduced staining for Bax, a proapoptotic regulator, is associated with poor breast cancer prognosis in the setting of metastatic disease Krajewski et al. 1995 ; . Furthermore, in this and a further metastatic study Sjostrom et al. 1998 ; , response to combination chemotherapy was significantly worse in tumours with reduced Bax and dofetilide.
Docetaxel chemo
1 the abbreviations used are: mtdna, mitochondrial dna; bnpage, blue-native page; cox, cytochrome c oxidase; alu, restriction endonuclease; alu-fish, alu-pcr repeats fluorescence in situ hybridization; tricine, n-[2-hydroxy-1, 1-bis hydroxymethyl ; ethyl]glycine.
FIG. 7. Effects of clonidine in the late spinal cat NG2, 121 days after spinalization. Same display as Fig. 3. AD: locomotion at 0.5 m s before any drug injection. EH: locomotion recorded 24 min after clonidine injection 100 g 100 l and dok.
Of vindesine, vincristine and vinblastine in patients with cancer. Cancer Treat Rev 1980; 7 Suppl ; : 17-24. Besenval M, Delgado M, Demarez JP et al. Safety and tolerance of Navelbine in phase I--II clinical studies. Semin Oncol 1989; 16 Suppl 4 ; : 37 10. Krikorian A, Breillout F. Vinorelbine NavelbineK ; . A new semisynthetic vinca-alkaloid. Oncology 1991; 14: 7-12. Depierre A, Lemarie E, Dabouis G et al. Efficacy of Navelbine NVB ; in non-small-cell lung cancer NSCLC ; . Semin Oncol 1989; 16 Suppl 4 ; : 26-9. Fumoleau P, Delgado FM, Delozier T et al. Phase II study of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11: 1245-52. Gebbia V, Testa A, Valeza R, Zerillo G et al. A pilot study of vinorelbine on a weekly schedule in recurrent and or metastatic squamous-cell carcinoma of the head and neck. Eur J Cancer 1993; 29: 1358-9. Testolin A, Recher G, Gristoferi V, Gaspanni G. Vinorelbine NVB ; in pretreated advanced head and neck squamous-cell carcinoma: A phase II study. Invest N Drugs 1994; 12: 231-4. Miller AB, Hoogsraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. In De Vita VT, Hellamn S, Rosenberg SA eds ; : Important Advances in Oncology. Philadelphia: JB Lippincott 1988; 121-42. Fleming TR. One sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143-51. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239-53. Jacobs C, Lyman G, Velez-Garcia E. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced head and neck squamous-cell carcinoma. J Clin Oncol 1992; 10: 257-63. Clavel M, Vermorken JB, Cognetti F. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine CABO ; versus cisplatin and 5-fluorouracil CF ; versus cisplatin in recurrent or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol 1994; 5: 521-6. Forastiere A, Metch B, Schuller D. Randomized comparison of CDDP plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck. A Southwest Oncology Group Study. J Clin Oncol 1992; 10: 1245-51. Liverpool Head and Neck Oncology Group. A phase III randomized trial of cisplatinium methotrexate, cisplatinium + methotrexate and cisplatinium + 5-FU in end stage squamous carcinoma of the head and neck. BrJ Cancer 1990; 61: 311-5. Forastiere A. Use of paclitaxel Taxol ; in squamous-cell carcinoma of the head and neck. Semin Oncol 1993; 20 Suppl 3 ; : 5660. Catimel G, Verweij J, Mattijssen V et al. Docetaxel Taxotere ; : An active drug for the treatment of patients with advanced squamous-cell carcinoma of the head and neck. Ann Oncol 1994; 5: 533-7. Canfield VA, Saxman SB, Kolodziej MA et al. Phase II trial of vinorelbine in advanced or recurrent squamous-cell carcinoma SCCa ; of the head and neck. Proc Soc Clin Oncol 1997; 16: 387a Abstr 1382 ; . Gebbia V, Testa A, Valenza R et al. Acute pain syndrome at tumour site in neoplasic patients treated with vinorelbine: Report of unusual toxicity. Eur J Cancer 1994, 30A 6 ; : 889.
Docetaxel pancreatic cancer
Monitoring mbc patients treated with herceptin-based therapies Women with MBC being treated with Herceptin and various chemotherapies n 107 ; 46, 73, 95 ; were monitored for changes in HER-2 neu ECD concentrations before treatment and then serially thereafter. Previous studies reported by Payne et al. 83 ; showed that Herceptin does not interfere with measuring ECD concentrations in the HER-2 neu assay used in all three of the studies described below. In an initial report by Schwartz et al. 74 ; in 2000, it was suggested that changes in serum HER-2 neu during Herceptin-based therapy might parallel the clinical course of disease; however, there were too few patients in the report to make a valid conclusion. In a 2002 study by Esteva et al. 95 ; , 30 MBC patients treated with docetaxel Taxotere ; and Herceptin were monitored for changes in serum HER-2 neu to determine whether serial changes would reflect the clinical course of disease. Studies showed that ECD concentrations decreased in 14 of 87% ; responding patients. As seen in studies of patients receiving conventional therapies, serial changes in serum HER-2 neu concentrations did parallel the clinical course of disease after Herceptin treatment and dolasetron.
To treatment. One case, which was not treatment-related, was observed in the control group. There was no increase in radiationrelated pulmonary toxicity radiation pneumonitis ; in the patients who received neoadjuvant docetaxel. Mild to moderate fluid retention was observed in 22 patients in the docetaxel arm and eight in the control arm. Elderly patients with chronic obstructive pulmonary disease and heart disease would be expected to suffer some degree of fluid retention. This may have been exacerbated by docetaxel treatment, but fluid retention was only ever mild and of no clinical significance. Two of the seven deaths which occurred in the docetaxel group were judged to be docetaxel-related as they arose from the infections mentioned above. No National Cancer Institute grade 4 laboratory abnormalities alkaline phosphatase, creatinine, AST, ALT, total bilirubin ; occurred.
First enzymatically activated taxotere prodrugs designed for adept and pmt emmanuel bouvier , sylvie thirot , fré dé ric schmidt , and claude monneret umr176 cnrs institut curie, section recherche, 26 rue d'ulm, 75248, paris cedex 05, france received 26 september 2003; accepted 12 december 200 available online 19 february 200 abstract described here are the syntheses and preliminary biological evaluations of the first two enzymatically activated prodrugs of docetaxel taxotere® reported to date and doral.
Docetaxel epimer
116 52.5 Universal Prince AUS ; Water Jump IRE ; White Heart GB ; 115 52 Anzillero GER ; Best of The Bests IRE ; Border Arrow GB ; Cagney BRZ ; Cape Town IRE ; Ciro USA ; Danger Over GB ; Falvelon AUS ; Germinis FR ; Hawksley Hill IRE ; Imperial Beauty USA ; Indigenous IRE ; Lazy Slusan USA ; Nicobar GB ; Nobo True USA ; Printemps CHI ; Proudwings GER ; Redattore BRZ ; Right Wing IRE ; Sandmason GB ; Say Florida Sandy USA ; State Shinto USA ; Subiaco GER.
Gemcitabine docetaxel and capecitabine
Gested that the anticonvulsive action of the drug was predominantly due to effects of AO-242 [54]. Jones and Davies [20] investigated the effects of AO-242 and AO-294 on audiogenic seizures in DBA 2 mice. The results clearly showed that only one enantiomer AO-242 ; was effective in this test, being undoubtedly the most important active constituent of the racemic mixture [20]. Chronic administration of losigamone in rats and mice once daily for 15 consecutive days ; did not affect either its ED50 values in MES test or the anticonvulsant activity of other prototype agents. These observations may suggest that chronic application of the drug does not result in tolerance development or enzyme induction [34] and dovonex.
CA] ; and among patients with HER-2 gene amplification by fluorescent in situ hybridization FISH ; as compared with FISH-nonamplified tumors 34% v 7% ; [8]. In preclinical studies, trastuzumab markedly potentiated the antitumor effects of selected chemotherapeutic agents [10-14]. In a landmark phase III trial published in 2001, women randomly assigned to receive trastuzumab in addition to chemotherapy experienced a statistically significantly longer time to progression and overall survival compared with their counterparts who received chemotherapy without trastuzumab [15]. Of note, overall response rates to chemotherapy plus trastuzumab were higher in FISH-positive patients compared with those who were FISH-negative 54% v 38% ; [15]. Thus patients selected for HER-2 amplification using FISH derived more clinical benefit from trastuzumab than patients selected by immunohistochemistry IHC ; [11, 16]. In previously untreated women with metastatic breast cancer, docetaxel given every 3 weeks has produced response rates ranging from 43% to 68% in various phase II trials [17-20]. A weekly schedule of docetaxel administration is also effective and well tolerated, with decreased hematologic toxicity [21, 22]. Furthermore, in patients with anthracycline-resistant disease, docetaxel yields response rates between 29% and 50% and is not associated with an increase in the incidence of cardiac toxicity occasionally produced by anthracyclines [23-26]. Thus the combination of docetaxel and trastuzumab is an attractive doublet for testing in women with advanced breast cancer, especially because preclinical data suggest that the combination of trastuzumab and docetaxel is synergistic [2, 3, 27, 28]. Therefore, the rationale for this phase II trial is as follows: docetaxel is at least as effective as doxorubicin as a single agent, there may be less cardiac toxicity with trastuzumab and docetaxel as compared with doxorubicin and trastuzumab, and there seems to be cytotoxic synergy when docetaxel is combined with trastuzumab [29]. The efficacy of weekly docetaxel in combination with weekly trastuzumab was tested in patients with HER-2 overexpressing metastatic breast cancer in a multi-institutional phase II pilot trial. Although HER-2 status was initially assessed using the HercepTest, as a correlative study, HER-2 neu overexpression was also determined by FISH using two different probes see below and docetaxel.
Docetaxel cisplatin 5fu
| Docetaxel more drug_side_effects11. Rice, P. L., Goldberg, R. J., Ray, E. C., Driggers, L. J., and Ahnen, D. J. Inhibition of extracellular signal-regulated kinase 1 2 phosphorylation and induction of apoptosis by sulindac metabolites. Cancer Res., 61: 15411547, 2001. Soh, J. Q., Mao, Y., Liu, L., Thompson, W. J., Pamukcu, R., and Weinstein, I. B. Protein kinase G activates the JNK1 pathway via phosphorylation. J. Biol. Chem., 276: 16406 16410, Skopinska-Rozewska, E., Piazza, G. A., Aommer, E., Pamukcu, R., Barcz, E., Filewska, M., Kupis, W., Caban, R., Rudzinski, P., Bogdan, J., Mlekodaj, S., and Sikorska, E. Inhibition of angiogenesis by sulindac and its sulfone metabolite FGN-2 ; : a potential mechanism for their antineoplastic properties. Int. J. Tissue React., 20: 85 89, Malkinson, A. M., Koski, K. M., Dwyer-Nield, L., Rice, P. L., Rioux, N., Castonguay, A., Ahnen, D. J., Thompson, H., Pamukcu, R., and Piazza, G. A. Inhibition of 4- methylnitrosoamino ; -1- 3-pyridyl ; 1-butanone-induced lung tumor formation by FGN-1 sulindac sulfone ; . Carcinogenesis Lond. ; , 19: 13531336, 1998. Thompson, H. J., Jiang, C., Lu, J., Mehta, R. G., Piazza, G. A., Paranka, N. S., Pamukcu, R., and Ahnen, D. J. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res., 15: 167271, 1997. Goluboff, E. T., Shabsigh, A., Saidi, J. A., Weinstein, I. B., Mitra, N., Heitjan, D., Piazza, G. A., Pamukcu, R., Buttyan, R., and Olsson C. A. Exisulind sulindac sulfone ; suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology, 53: 440 445, Soriano, A. F., Helfrich, B., Chan, D. C., Heasley, L. E., Bunn, P. A., Jr., and Chou, T. C. Synergistic effects of new chemoprentitive and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res., 59: 6178 6184, McLemore, T. L., Liu, M. C., Blacker, P. C., Gregg, M., Alley, M. C., Abbott, B. J., Shoemaker, R. H., Bohlman, M. E., Litterst, C. C., Hubbard, W. C., Brennan, R. H., McMahon, J. B., Fine, D. L., Eggleston, J. C., Mayo, J. G., and Boyd, M. R. Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice. Cancer Res., 47: 51325140, 1987. Howard, R. B., Chu, H., Zeligman, B. E., Marcell, T., Bunn, P. A., McLemore, T. L., Mulvin, D. W., Cowen, M. E., and Johnston, M. R. Irradiated nude rat model for orthotopic human lung cancers. Cancer Res., 51: 3274 3280, Carmichael, J., Mitchell, J. B., DeGraff, W. G., Gamson, J., Gazdar, A. F., Johnson, B. E., Glatstein, E., and Minna, J. D. Chemosensitivity testing of human lung cancer cell lines using the MTT assay. Br. J. Cancer, 57: 540 547, Chou, T. C., and Talalay, P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol. Sci., 4: 450 454, Chan, D. C., Soriano, A., Helfrich, B., Zhang, Z. Y., Pamukcu, R., Piazza, G. A., and Bunn, P. A., Jr. Synergistic effects of exisulind with conventional chemopreventive and therapeutic agents against human lung cancer cells in vitro and in vivo. Proc. Am. Soc. Clin. Oncol., 18: 488a, 1999. Whitehead, C. M., Earle, K. A., Xu, S., Chan, D., Zhao, T., Alila, H., Pamukcu, R., Klein-Szanto, A., Bunn, P., Thompson, W. J., and Piazza, G. Efficacy of exisulind and docetaxel combination in an orthotopic human NSCLC rat model involves apoptosis induction and angiogenesis. Proc. Am. Assoc. Cancer Res., 42: 362, 2001. Pierson, A. S., Gustafson, D., Long, M., Chan, D. C., Kelly, K., Bunn, P. A., Mikule, C., Holden, S. N., Persky, M., and Eckhardt, S. G. A phase I and pharmacologic PK ; study of exisulind combined with taxotere in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol., 20: 120a, 2001 and doxil.
Gemcitabine docetaxel pancreatic
Table 1. Effects on KYSE30 cancer cell growth of the combination of EGFR inhibitors and cytotoxic drugs Sequence Gefitinib followed by chemotherapy CI at IC50 ; Chemotherapy followed by gefitinib CI at IC50 ; ZD6474 followed by chemotherapy CI at IC50 ; Chemotherapy followed by ZD6474 CI at IC50 ; Cetuximab followed by chemotherapy CI at IC50 ; Chemotherapy followed by cetuximab CI at IC50 ; Cisplatin 1.85 0.11 1.92 Carboplatin 1.79 0.14 1.74 Oxaliplatin 1.65 0.12 1.68 Docetaxel 1.47 0.26 1.57 Paclitaxel 1.68 0.29 1.71.
Until November 2002, serum insulin-like growth factor I IGF-I ; was determined by radioimmunoassay after acid-ethanol precipitation of the binding proteins Nichols Institute Diagnostics, San Juan Capistrano, CA, USA ; . Then a chemiluminescence immunoassay Nichols Advantagew System ; was introduced 32 ; . Long-term reproducibility, measured during a time period of O1 year, showed a CV !9% in the concentration range of 130850 mg l. The assay detection limit was 30 mg l. All measurements were performed in a central laboratory and doxorubicin
|
The results of the data extraction and quality assessment for each study of clinical effectiveness are presented in structured tables and as a narrative summary. Where appropriate, outcomes were synthesised using formal analytic approaches. For the cost-effectiveness section of the report, details of each identified published economic evaluation, together with a critical appraisal of its quality, are presented in structured tables. A new cost-effectiveness model was developed in order to establish the cost-effectiveness of docetaxel compared with a range of potential comparators. The model was developed to estimate costs from the perspective of the UK NHS and health outcomes in terms of life-years gained and quality-adjusted life-years QALYs ; for the full range of relevant treatment strategies. A simple two-state Markov model was constructed to calculate mean survival and to account for discounting. The model was run for a time horizon of 15-years in order to obtain a robust estimate of mean survival. A separate review was undertaken to identify sources of utility data required to estimate QALYs. Sensitivity analyses were also undertaken to explore the robustness of the main analysis to alternative assumptions related to quality of life. Monte Carlo simulation was used to propagate uncertainty in input parameters through the model in such a way that the results of the analysis could be presented with their uncertainty. The impact of uncertainty surrounding the decision was established using value of information and implementation approaches and docusate.
Member: NATAS, SOA Based near Nashville, I provide complete Steadicam services for video, film and HD production. Experienced in operating from vehicles, helicopters, ATVs. See my website for credits and dronabinol.
Docetaxel oxaliplatin gastric cancer
Docetaxel manufacturer
Pneumoconiosis more for_patients, inguinal triangle, physician ratings free, hirsutism thyroid and hepatocellular carcinoma resection. Epidermal inclusion cyst cytology, liquid nitrogen kit, acid-base balance video and hydrocele painful or palpitations eating.
Docetaxel weekly
Docetasel, docegaxel, rocetaxel, doce5axel, docetaxeel, doceetaxel, docetaxell, docdtaxel, doceaxel, docetaxxel, docetaxe, doxetaxel, docrtaxel, docetaxdl, doceraxel, dicetaxel, doocetaxel, dodetaxel, doectaxel, ocetaxel.
Docetaxel brands
Docetaxel medicine, docetaxel chemo, docetaxel pancreatic cancer, docetaxel epimer and gemcitabine docetaxel and capecitabine. Docetaxel cisplatin 5fu, docetaxel more drug_side_effects, gemcitabine docetaxel pancreatic and docetaxel oxaliplatin gastric cancer or docetaxel manufacturer.
|
